FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review - TEVA News | RalliesFDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review
T
TEVA• FDA accepts ecopipam NDA and grants priority review
- FDA accepted Teva’s NDA for ecopipam to treat pediatric Tourette syndrome, granting priority review.
- PDUFA action date set for late Q1 2027.
- Ecopipam is a first-in-class selective D1 receptor antagonist with orphan drug designation.
•
